Genmab — August 2013
-
lidt malurt: Vi har i første halvår 2013 oplevet vækst i salget af vores egen software på 4%. Den stigning er lavere end forventet men skal ses i lyset af en generel tilbagegang i tredjeparts- softwaresalget på 12%.
-
så kom mr. market med
-
solgte den nye posiion i 2,56...
-
og 2,57
-
http://finance.yahoo.com/q?s=GNMSF 55.000 stk køb/salg ?
-
For the record, J&J's collaboration with Pharmacyclics along with its breakthrough designation for daratumumab gives it four breakthrough designations on two drugs.
Read more: Novartis wins a record breakthrough therapy designation for orphan drug - FierceBiotech http://www.fiercebiotech.com/story/novartis-win-record-breakthrough-therapy-designation-orphan-drug/2013-08-20#ixzz2caMIVNW3
Subscribe at FierceBiotech -
-
The efficacy and toxicity of ofatumumab-based CIT compare favorably to our historical trials of rituximab-based CIT using an identical chemotherapy backbone (n = 64). Time to retreatment also appeared longer for ofatumumab-based CIT (free of retreatment at 24 months: 86% [95% confidence interval = 75-99] versus 68% [95% confidence interval = 56-81] for rituximab-based CIT).
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind